Genetic Information and Insurance: Legal and Ethical Issues

Legal Framework

The Genetic Information Nondiscrimination Act (GINA) of 2008 prohibits health insurers from using genetic information in coverage and pricing decisions. GINA defines genetic information broadly to include an individual's genetic test results, the genetic test results of family members, and family medical history. The law prevents health insurers from requiring or requesting genetic testing, using genetic information to make enrollment or coverage decisions, and adjusting premiums based on genetic characteristics. GINA also prohibits employers from using genetic information in employment decisions, providing complementary protections in both the insurance and employment contexts.

However, GINA does not apply to life insurance, disability insurance, or long-term care insurance. This gap in federal protection means that applicants for these products may be asked about genetic test results as part of the underwriting process, and insurers may use this information in their coverage and pricing decisions. Some states have enacted their own laws extending genetic nondiscrimination protections to these lines, but coverage is inconsistent across jurisdictions, creating a patchwork of regulatory standards that vary by state and insurance product.

International Approaches

Different countries have adopted different approaches to regulating the use of genetic information in insurance. In countries with universal health coverage, the debate focuses primarily on life and income protection insurance, since health coverage is guaranteed regardless of genetic status. The United Kingdom's Code on Genetic Testing and Insurance represents a voluntary moratorium approach, in which insurers have agreed not to use predictive genetic test results for policies below specified coverage limits. This approach provides consumer protection while preserving insurers' ability to use genetic information for very large policies where the adverse selection risk is greatest.

Canada enacted the Genetic Non-Discrimination Act in 2017, which prohibits insurers from requiring or using genetic test results in any line of insurance. Several European countries have similar prohibitions. In contrast, many Asian and developing countries have not yet addressed the issue legislatively, leaving the use of genetic information in insurance largely unregulated. The diversity of regulatory approaches reflects different societal values regarding privacy, solidarity, and individual risk assessment.

The Actuarial Perspective on Genetic Information

From a pure actuarial perspective, genetic information could improve risk classification accuracy for products covering mortality and morbidity risk. Genetic test results can provide information about an individual's predisposition to diseases such as breast cancer (BRCA mutations), Huntington's disease, cystic fibrosis, and various cardiovascular conditions. This information, combined with traditional underwriting factors, could theoretically produce more accurate pricing for life and health insurance products.

However, the actuarial value of genetic information is more nuanced than it might initially appear. Most genetic test results indicate a predisposition to disease, not a certainty of developing it. The penetrance of genetic mutations (the probability that a person with a mutation will actually develop the associated disease) varies widely across different conditions. Environmental factors, lifestyle choices, and medical interventions can significantly modify the risk associated with a genetic predisposition. For many conditions, genetic information adds only marginally to the predictive power already available from family medical history, which is routinely used in underwriting.

Adverse Selection Concerns

Adverse selection is the primary actuarial concern in debates about genetic information and insurance. If applicants know their genetic risk but insurers cannot use this information, high-risk individuals may purchase more coverage while low-risk individuals purchase less. This information asymmetry can lead to a deterioration of the risk pool, requiring premium increases that further discourage low-risk individuals from participating, potentially creating an adverse selection spiral.

Research on the magnitude of adverse selection from genetic information has produced mixed results. Some studies have found evidence of adverse selection behavior among individuals who know they carry mutations for specific diseases, while others have found that the effect is modest and does not threaten market stability. The impact of genetic information on adverse selection depends on several factors: the severity and penetrance of the genetic condition, the availability and cost of genetic testing, the size of the affected population, and the behavioral response of individuals to genetic risk information.

Actuaries have proposed several mechanisms to mitigate adverse selection while maintaining restrictions on the use of genetic information. These include maintaining reasonable policy limits below which genetic testing cannot be required, using pooling mechanisms to spread genetic risk across the insured population, and adjusting underwriting practices to account for the potential information asymmetry created by genetic testing restrictions.

Ethical Dimensions

The use of genetic information in insurance raises profound ethical concerns that extend beyond actuarial considerations. Genetic discrimination, the differential treatment of individuals based on their genetic characteristics, conflicts with principles of fairness that prohibit discrimination based on immutable characteristics beyond an individual's control. Unlike behavioral risk factors (smoking, dangerous hobbies) that involve individual choice, genetic characteristics are inherited and cannot be modified.

The deterrence effect is another important ethical consideration. If individuals fear that genetic test results will affect their insurance coverage or pricing, they may avoid beneficial genetic testing. This could prevent individuals from receiving early diagnoses, participating in preventive care programs, or contributing to genetic research. Public health experts argue that the societal benefits of widespread genetic testing (earlier disease detection, targeted prevention, personalized medicine) outweigh the actuarial benefits of using genetic information for risk classification.

The Future of Genetics and Insurance

The rapid advancement of genomic science and the decreasing cost of genetic testing are making this issue increasingly urgent. Direct-to-consumer genetic testing services have made genetic information widely accessible, with millions of consumers obtaining genetic risk information outside the traditional medical system. As genetic testing becomes more comprehensive and accurate, the potential information asymmetry between consumers and insurers grows, intensifying both the adverse selection concerns and the privacy and fairness considerations.

Polygenic risk scores, which combine the effects of many genetic variants to estimate overall disease risk, represent the next frontier in genetic risk assessment. These scores can predict risk for common complex diseases (heart disease, diabetes, certain cancers) with increasing accuracy. As polygenic risk scores become more powerful, the debate about their use in insurance will intensify, requiring actuaries, regulators, and ethicists to engage in ongoing dialogue about the appropriate balance between risk classification accuracy and societal values.

Study Relevance

Genetic information and insurance topics appear on SOA and CAS exams covering ethics, regulation, and health insurance. Key concepts include the scope and limitations of GINA, the information asymmetry problem created by restrictions on genetic information use, the adverse selection dynamics in markets with asymmetric genetic information, and the ethical framework for evaluating the use of immutable personal characteristics in insurance pricing. These topics illustrate the intersection of actuarial science with law, ethics, and public policy, reflecting the broader responsibilities of the actuarial profession.